Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$26.16 +0.7%	$27.93	$0.94 ▼ $79.02	$184.27M	-6.01	827,291 shs	25,311 shs
IMMX Immix Biopharma	$2.97 +1.7%	$2.34	$1.26 ▼ $3.12	$82.79M	0.24	153,736 shs	278,471 shs
PLX Protalix BioTherapeutics	$1.45 -3.3%	$1.53	$0.82 ▼ $3.10	$115.43M	-0.23	601,033 shs	514,630 shs
PROK ProKidney	$3.15 -10.5%	$1.33	$0.46 ▼ $7.13	$922M	1.26	3.62 million shs	6.55 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	0.00%	+5.44%	-7.20%	-20.99%	+2,116.95%
IMMX Immix Biopharma	0.00%	+12.08%	+24.27%	+78.92%	+36.24%
PLX Protalix BioTherapeutics	0.00%	+2.84%	+3.57%	-44.44%	+28.32%
PROK ProKidney	0.00%	-30.62%	+352.39%	+298.28%	+36.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRUG Bright Minds Biosciences	1.6667 of 5 stars	3.6	2.0	0.0	2.5	0.0
IMMX Immix Biopharma	3.1192 of 5 stars	3.5	5.0	0.0	3.3	0.6
PLX Protalix BioTherapeutics	2.2977 of 5 stars	3.5	3.0	0.0	0.0	1.9
PROK ProKidney	3.5425 of 5 stars	3.2	4.0	3.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	218.23% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	135.69% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	934.48% Upside
PROK ProKidney	2.40	Hold	$6.25	98.41% Upside

Current Analyst Ratings Breakdown

Latest IMMX, PLX, PROK, and DRUG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
PLX Protalix BioTherapeutics	$59.76M	1.93	$0.08 per share	17.80	$0.47 per share	3.09
PROK ProKidney	$80K	11,525.06	N/A	N/A	($3.41) per share	-0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.68	N/A	-21.03%	-30.89%	-11.74%	N/A
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)

Latest IMMX, PLX, PROK, and DRUG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	DRUG Bright Minds Biosciences	-$0.59	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q1 2025	IMMX Immix Biopharma	-$0.21	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	PROK ProKidney	-$0.14	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	126.01	126.01
IMMX Immix Biopharma	N/A	1.80	1.80
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PROK ProKidney	N/A	10.96	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
IMMX Immix Biopharma	11.26%
PLX Protalix BioTherapeutics	16.53%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
IMMX Immix Biopharma	55.40%
PLX Protalix BioTherapeutics	6.50%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

IMMX, PLX, PROK, and DRUG Headlines

Recent News About These Companies

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

July 20 at 2:34 AM | insidermonkey.com

ProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?

July 18 at 12:35 PM | marketbeat.com

ProKidney Corp. (NASDAQ:PROK) Receives $5.67 Average Price Target from Analysts

July 18 at 2:23 AM | americanbankingnews.com

PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 17 at 1:01 PM | zacks.com

Best Momentum Stocks to Buy for July 17th

July 17 at 11:01 AM | zacks.com

New Strong Buy Stocks for July 17th

July 17 at 6:40 AM | zacks.com

ProKidney gains pivotal therapy advancement step with FDA

July 17 at 6:15 AM | journalnow.comJ

ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?

July 16, 2025 | zacks.com

ProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst Upgrade

July 16, 2025 | americanbankingnews.com

ProKidney (NASDAQ:PROK) Shares Gap Up on Analyst Upgrade

July 16, 2025 | americanbankingnews.com

Promising clinical trial results give ProKidney share price major boost

July 15, 2025 | journalnow.comJ

ProKidney stock soars after FDA confirms accelerated approval pathway

July 15, 2025 | in.investing.com

ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial

July 15, 2025 | marketwatch.com

ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy

July 15, 2025 | msn.com

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

July 15, 2025 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst Upgrade

July 15, 2025 | marketbeat.com

ProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from Brokerages

July 15, 2025 | marketbeat.com

ProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and Diabetes

July 15, 2025 | quiverquant.comQ

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

July 15, 2025 | globenewswire.com

ProKidney (NASDAQ:PROK) Shares Gap Up Following Analyst Upgrade

July 14, 2025 | marketbeat.com

Guggenheim Increases ProKidney (NASDAQ:PROK) Price Target to $7.00

July 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, PLX, PROK, and DRUG Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$26.16 +0.17 (+0.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.27 +0.11 (+0.42%)

As of 07/18/2025 07:35 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Immix Biopharma NASDAQ:IMMX

$2.97 +0.05 (+1.71%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.91 -0.06 (-2.02%)

As of 07/18/2025 07:53 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Protalix BioTherapeutics NYSE:PLX

$1.45 -0.05 (-3.33%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.45 0.00 (0.00%)

As of 07/18/2025 04:09 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

ProKidney NASDAQ:PROK

$3.15 -0.37 (-10.51%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.04 (+1.43%)

As of 07/18/2025 07:59 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time